PlexBio Co (6572) Fair Value & Analysis
Healthcare · TW · Market cap 757M TWD
Fair value as of: Jun 24, 2026
Analysis
PlexBio Co (6572) currently trades at 7.35 TWD, while our model-based Fair Value estimate is 8.99 TWD — implying the stock looks roughly 22.3% undervalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: low) — always confirm before acting.
About the company
PlexBio Co., Ltd. develops and manufactures in vitro diagnostic reagents for molecular biology and immunology projects. It offers workflow navigation services; automated sample preparation kits; IntelliPlex platform that is designed for pCode technology with throughput sample-to-answer multiplexing assays; oncology assays, a portfolio for advanced molecular testing; and pCode coupling buffer sets. PlexBio Co., Ltd. was founded in 2009 and is based in Taipei, Taiwan.
Open the full interactive analysis →
Similar stocks
Frequently asked questions
Is PlexBio Co (6572) undervalued?
What is the fair value of 6572?
What is the quality score of 6572?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.